Many companies with the best products in the market took years to reach profitability, so anything sub 50c will be cheap in the LT. It was already at $1.80 / 18c about 2 or 2 1/2 years ago with hardly anything to sell - now based on profits the valuation will be more realistic in coming months / years. No reasons why not jumping over $1 in the future.
GLTA
Ann: Admedus Receives FDA Clearance for CardioCel 3D, page-76
-
- There are more pages in this discussion • 59 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.04 |
Change
-0.110(0.73%) |
Mkt cap ! $292.1M | |||
| Open | High | Low | Value | Volume |
| $15.35 | $15.35 | $15.00 | $52.54K | 3.458K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 44 | $15.04 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.18 | 153 | 2 |
View Market Depth
| Last trade - 12.45pm 31/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |